A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT06785116

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06785116
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06785116. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-02 (actual); primary completion 2028-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
Acronym
DAPA-HP
Condition
Gestational Hypertension
Condition
Hypertension in Pregnancy
Condition
Pre-Eclampsia
Condition
Superimposed Pre-Eclampsia
Condition
Cardiovascular Complication
Intervention (Drug)
Placebo
Intervention (Drug)
Dapagliflozin 10mg Tab
Lead sponsor
University of Michigan (class: other)
Collaborator
Society for Maternal-Fetal Medicine Foundation (class: not stated)
Collaborator
American Association of Obstetricians and Gynecologists Foundation (class: not stated)

Record details

Record id
cardio:ct-nct06785116
Content hash
f7ea1fc32310902174453f7344a9d8f2bebf9b83a2ccd014376d85e096fd08ff